Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared a post on LinkedIn about a paper by Kexin Koh et al. published in Cancer Discovery:
“Cancer cachexia = an underdiagnosed, lethal syndrome.
- Affects up to 80% in pancreatic CA, 40% in lung.
- It’s not just weight loss – think systemic inflammation, altered metabolism, fat/muscle wasting.
- GDF-15, IL-6, activin A are key molecular drivers.
- A major unmet need in cancer patients.”
Amy C. Moore, Director, Patient Engagement and Advocacy at Summit Therapeutics, shared this post, adding:
“I am honored to be part of Team CANCAN, funded by Cancer Grand Challenges, to understand the causes of and find new interventions for cancer cachexia. Learn more about Team CANCAN’s work: CANCAN | Cancer Grand Challenges.”
Title: Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies
Authors: Kexin Koh, Rachel Scott, Elizabeth M. Cespedes Feliciano, Tobias Janowitz, Marcus D. Goncalves, Eileen P. White, Barry J.A. Laird, Kerstin Haase, Mariam Jamal-Hanjani
You can read the Full Article on Cancer Discovery.
More posts featuring Jean-Charles Soria and Amy C. Moore.
